Skip to main content
Top
Published in: BMC Infectious Diseases 1/2014

Open Access 01-12-2014 | Research article

Predictors of hospital mortality among septic ICU patients with Acinetobacter spp.bacteremia: a cohort study

Authors: Andrew F Shorr, Marya D Zilberberg, Scott T Micek, Marin H Kollef

Published in: BMC Infectious Diseases | Issue 1/2014

Login to get access

Abstract

Background

We hypothesized that among septic ICU patients with Acinetobacter spp. bacteremia (Ac-BSI), carbapenem-resistant Acinetobacter spp. (CRAc) increase risk for inappropriate initial antibiotic therapy (non-IAAT), and non-IAAT is a predictor of hospital death.

Methods

We conducted a retrospective cohort study of adult septic ICU patients with Ac-BSI. Non-IAAT was defined as exposure to initially prescribed antibiotics not active against the pathogen based on in vitro susceptibility testing, and having no exposure to appropriate antimicrobial treatment within 24 hours of drawing positive culture. We compared patients who died to those who survived, and derived regression models to identify predictors of hospital mortality and of non-IAAT.

Results

Out of 131 patients with Ac-BSI, 65 (49.6%) died (non-survivors, NS). NS were older (63 [51, 76] vs. 56 [45, 66] years, p = 0.014), and sicker than survivors (S): APACHE II (24 [19, 31] vs. 18 [13, 22], p < 0.001) and Charlson (5 [2, 8] vs. 3 [1, 6], p = 0.009) scores. NS were also more likely than S to require pressors (75.4% vs. 42.4%, p < 0.001) and mechanical ventilation (75.4% vs. 53.0%, p = 0.008). Both CRAc (69.2% vs. 47.0%, p = 0.010) and non-IAAT (83.1% vs. 59.1%, p = 0.002) were more frequent among NS than S. In multivariate analyses, non-IAAT emerged as an independent predictor of hospital death (risk ratio [RR] 1.42, 95% confidence interval [CI] 1.10-1.58), while CRAc was the single strongest predictor of non-IAAT (RR 2.66, 95% CI 2.43-2.72).

Conclusions

Among septic ICU patients with Ac-BSI, non-IAAT predicts mortality. Carbapenem resistance appears to mediate the relationship between non-IAAT and mortality.
Literature
2.
go back to reference Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008, 29: 996-1011. 10.1086/591861.CrossRefPubMed Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol. 2008, 29: 996-1011. 10.1086/591861.CrossRefPubMed
3.
go back to reference Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013, 34: 1-14. 10.1086/668770.CrossRefPubMed Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S: Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol. 2013, 34: 1-14. 10.1086/668770.CrossRefPubMed
4.
go back to reference Zilberberg MD, Shorr AF: Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med. 2013, 8: 559-563.PubMed Zilberberg MD, Shorr AF: Prevalence of multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae among specimens from hospitalized patients with pneumonia and bloodstream infections in the United States from 2000 to 2009. J Hosp Med. 2013, 8: 559-563.PubMed
5.
go back to reference Zilberberg MD, Shorr AF: Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol. 2013, 34: 940-946. 10.1086/671740.CrossRefPubMed Zilberberg MD, Shorr AF: Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol. 2013, 34: 940-946. 10.1086/671740.CrossRefPubMed
6.
go back to reference Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH: Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007, 51: 3568-3573. 10.1128/AAC.00851-07.CrossRefPubMedPubMedCentral Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH: Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007, 51: 3568-3573. 10.1128/AAC.00851-07.CrossRefPubMedPubMedCentral
7.
go back to reference Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002, 122: 262-268. 10.1378/chest.122.1.262.CrossRefPubMed Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH: Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002, 122: 262-268. 10.1378/chest.122.1.262.CrossRefPubMed
8.
go back to reference Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996, 22: 387-394. 10.1007/BF01712153.CrossRefPubMed Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996, 22: 387-394. 10.1007/BF01712153.CrossRefPubMed
9.
go back to reference Zilberberg MD, Shorr AF, Micek MT, Mody SH, Kollef MH: Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest. 2008, 134: 963-968. 10.1378/chest.08-0842.CrossRefPubMed Zilberberg MD, Shorr AF, Micek MT, Mody SH, Kollef MH: Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest. 2008, 134: 963-968. 10.1378/chest.08-0842.CrossRefPubMed
10.
go back to reference Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011, 39: 46-51. 10.1097/CCM.0b013e3181fa41a7.CrossRefPubMed Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH: Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011, 39: 46-51. 10.1097/CCM.0b013e3181fa41a7.CrossRefPubMed
11.
go back to reference Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999, 115: 462-474. 10.1378/chest.115.2.462.CrossRefPubMed Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999, 115: 462-474. 10.1378/chest.115.2.462.CrossRefPubMed
12.
go back to reference Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10.CrossRefPubMed Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003, 31: 2742-2751. 10.1097/01.CCM.0000098031.24329.10.CrossRefPubMed
13.
go back to reference Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005.CrossRefPubMed Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med. 2003, 115: 529-535. 10.1016/j.amjmed.2003.07.005.CrossRefPubMed
14.
go back to reference Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9.CrossRefPubMed Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9.CrossRefPubMed
15.
go back to reference Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83af.CrossRefPubMed Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013, 41: 580-637. 10.1097/CCM.0b013e31827e83af.CrossRefPubMed
16.
go back to reference Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001, 29: 1303-1310. 10.1097/00003246-200107000-00002.CrossRefPubMed
17.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed
18.
go back to reference Zhang J, Kai YF: What’s the Relative Risk?: A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes. JAMA. 1998, 280: 1690-1691. 10.1001/jama.280.19.1690.CrossRefPubMed Zhang J, Kai YF: What’s the Relative Risk?: A Method of Correcting the Odds Ratio in Cohort Studies of Common Outcomes. JAMA. 1998, 280: 1690-1691. 10.1001/jama.280.19.1690.CrossRefPubMed
19.
go back to reference Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007, 59: 525-530. 10.1093/jac/dkl499.CrossRefPubMed Kwon KT, Oh WS, Song JH, Chang HH, Jung SI, Kim SW, Ryu SY, Heo ST, Jung DS, Rhee JY, Shin SY, Ko KS, Peck KR, Lee NY: Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia. J Antimicrob Chemother. 2007, 59: 525-530. 10.1093/jac/dkl499.CrossRefPubMed
20.
go back to reference Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N: Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agnets. 2009, 34: 575-579. 10.1016/j.ijantimicag.2009.07.006.CrossRef Erbay A, Idil A, Gozel MG, Mumcuoglu I, Balaban N: Impact of early appropriate antimicrobial therapy on survival in Acinetobacter baumannii bloodstream infections. Int J Antimicrob Agnets. 2009, 34: 575-579. 10.1016/j.ijantimicag.2009.07.006.CrossRef
21.
go back to reference Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007, 13: 97-103. 10.3201/eid1301.060716.CrossRefPubMedPubMedCentral Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A: Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis. 2007, 13: 97-103. 10.3201/eid1301.060716.CrossRefPubMedPubMedCentral
22.
go back to reference Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY: Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2005, 38: 127-136.PubMed Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, Liu CY: Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2005, 38: 127-136.PubMed
23.
go back to reference Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM: Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J. 2005, 35: 599-603. 10.1111/j.1445-5994.2005.00925.x.CrossRefPubMed Choi JY, Park YS, Kim CO, Yoon HJ, Shin SY, Kim YA, Song YG, Yong D, Lee K, Kim JM: Mortality risk factors of Acinetobacter baumannii bacteraemia. Intern Med J. 2005, 35: 599-603. 10.1111/j.1445-5994.2005.00925.x.CrossRefPubMed
24.
go back to reference Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P: Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006, 57: 1251-1254. 10.1093/jac/dkl130.CrossRefPubMed Falagas ME, Kasiakou SK, Rafailidis PI, Zouglakis G, Morfou P: Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006, 57: 1251-1254. 10.1093/jac/dkl130.CrossRefPubMed
25.
go back to reference Metan G, Sariguzel F, Sumerkan B: Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med. 2009, 20: 540-544. 10.1016/j.ejim.2009.05.005.CrossRefPubMed Metan G, Sariguzel F, Sumerkan B: Factors influencing survival in patients with multi-drug-resistant Acinetobacter bacteraemia. Eur J Intern Med. 2009, 20: 540-544. 10.1016/j.ejim.2009.05.005.CrossRefPubMed
26.
go back to reference Esterly JS, Griffith M, Qi C, Manczynski M, Postelnick MJ, Scheetz MH: Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother. 2011, 55: 4844-4849. 10.1128/AAC.01728-10.CrossRefPubMedPubMedCentral Esterly JS, Griffith M, Qi C, Manczynski M, Postelnick MJ, Scheetz MH: Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother. 2011, 55: 4844-4849. 10.1128/AAC.01728-10.CrossRefPubMedPubMedCentral
27.
go back to reference Maragakis LL, Perl TM: Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008, 46: 1254-1263. 10.1086/529198.CrossRefPubMed Maragakis LL, Perl TM: Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008, 46: 1254-1263. 10.1086/529198.CrossRefPubMed
29.
go back to reference Kiratisin P, Apisarnthanarak A, Kaewdaeng S: Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010, 36: 243-246. 10.1016/j.ijantimicag.2010.04.011.CrossRefPubMed Kiratisin P, Apisarnthanarak A, Kaewdaeng S: Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010, 36: 243-246. 10.1016/j.ijantimicag.2010.04.011.CrossRefPubMed
30.
go back to reference Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC: Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011, 70: 380-386. 10.1016/j.diagmicrobio.2011.03.003.CrossRefPubMed Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, Chang SC: Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis. 2011, 70: 380-386. 10.1016/j.diagmicrobio.2011.03.003.CrossRefPubMed
31.
go back to reference Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP: Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011, 204: 340-347. 10.1093/infdis/jir270.CrossRefPubMed Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O’Sullivan MV, Anderson TL, Roberts SA, Gao W, Christiansen KJ, Coombs GW, Johnson PD, Howden BP: Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011, 204: 340-347. 10.1093/infdis/jir270.CrossRefPubMed
32.
go back to reference Cervera C, Castaneda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericas JM, Falces C, Armero Y, Almela M, Ninot S, Pare JC, Mestres CA, Gatell JM, Marco F, Miro JM: Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis. 2014, 58: 1668-1675. 10.1093/cid/ciu183.CrossRefPubMed Cervera C, Castaneda X, de la Maria CG, del Rio A, Moreno A, Soy D, Pericas JM, Falces C, Armero Y, Almela M, Ninot S, Pare JC, Mestres CA, Gatell JM, Marco F, Miro JM: Effect of vancomycin minimal inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus endocarditis. Clin Infect Dis. 2014, 58: 1668-1675. 10.1093/cid/ciu183.CrossRefPubMed
33.
go back to reference World Health Organization: Antimicrobial resistance: Global report on surveillance 2014. Available at URL: Please check that the following URLs are working. If not, please provide alternatives: http://www.who.int/drugresistance/documents/surveillancereport/en/; accessed June 5, 2014. World Health Organization: Antimicrobial resistance: Global report on surveillance 2014. Available at URL: Please check that the following URLs are working. If not, please provide alternatives: http://​www.​who.​int/​drugresistance/​documents/​surveillancerepo​rt/​en/​; accessed June 5, 2014.
Metadata
Title
Predictors of hospital mortality among septic ICU patients with Acinetobacter spp.bacteremia: a cohort study
Authors
Andrew F Shorr
Marya D Zilberberg
Scott T Micek
Marin H Kollef
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2014
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-014-0572-6

Other articles of this Issue 1/2014

BMC Infectious Diseases 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.